A report recently published in Cell Cycle supports the preferential effectiveness of ONCONASE toward tumor cells, and underlines the effectiveness of the drug in treating malignant mesothelioma. Cell Cycle is a scientific journal that focuses on molecular aspects of cancer research, and which is dedicated to research on the cell cycle and cancer.
The report is the result of collaborative research conducted at the Brander Cancer Research Institute and the Department of Pathology at New York Medical College, in conjunction with the drug manufacturer, Alfacell.
The new study provides further evidence of the impact ONCONASE has on the RNAi mechanism, said Alfacell CEO Kuslima Shogen in a company news release. Shogen said it also provides evidence as to why ONCONASE helps sensitize cells to other antitumor agents.
According to the release, “The study demonstrated that silencing the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene (an abundant and ubiquitously expressed housekeeping gene) in human lung adenocarcinoma A549 cells by siRNA was effectively prevented by ONCONASE. While transfection of cells with GAPDH siRNA reduced expression of this protein by nearly 70 percent, the expression was restored in the cells exposed to ONCONASE for 48 or 72 hours. The data thus provide evidence that one of the targets of ONCONASE (ranpirnase) is siRNA.”
Results of ONCONASE Phase III clinical trials, “demonstrate significant efficacy in patients with malignant mesothelioma that failed prior chemotherapy,” according to Alfacell information. The drug utilizes a proprietary ribonuclease (RNase) technology that targets cancer cells while sparing normal cells.
The report is the result of collaborative research conducted at the Brander Cancer Research Institute and the Department of Pathology at New York Medical College, in conjunction with the drug manufacturer, Alfacell.
The new study provides further evidence of the impact ONCONASE has on the RNAi mechanism, said Alfacell CEO Kuslima Shogen in a company news release. Shogen said it also provides evidence as to why ONCONASE helps sensitize cells to other antitumor agents.
According to the release, “The study demonstrated that silencing the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene (an abundant and ubiquitously expressed housekeeping gene) in human lung adenocarcinoma A549 cells by siRNA was effectively prevented by ONCONASE. While transfection of cells with GAPDH siRNA reduced expression of this protein by nearly 70 percent, the expression was restored in the cells exposed to ONCONASE for 48 or 72 hours. The data thus provide evidence that one of the targets of ONCONASE (ranpirnase) is siRNA.”
Results of ONCONASE Phase III clinical trials, “demonstrate significant efficacy in patients with malignant mesothelioma that failed prior chemotherapy,” according to Alfacell information. The drug utilizes a proprietary ribonuclease (RNase) technology that targets cancer cells while sparing normal cells.
No comments:
Post a Comment